Results 211 to 220 of about 143,629 (328)

Analgesic opioids in pregnancy and placental malperfusion-related disorders: a population-based cohort study [PDF]

Jonathan Brett, Claudia Bruno, Bianca Varney, Alys Havard, Antonia Shand, Krista F. Huybrechts, Helga Zoëga   +6 more
openalex   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

The rising burden of drug use disorders in the Americas, 2000-2021. [PDF]

Rev Panam Salud Publica
Martinez R, Zapata MA, Tausch A, Lange S, Russell C, Hennis A, E Souza RO.   +6 more
europepmc   +1 more source

Association Between Opioid Use and Emergency Department Visits for Spine-Related Disorders

Chijioke Okeke, Godwin Okoye, J. Douglas Thornton   +2 more
openalex   +2 more sources

Transmucosal fentanyl-related opioid use disorder in a cancer survivor [PDF]

Salim Mezaache, Christophe Cutarella, Élisabeth Frauger, Joëlle Micallef   +3 more
openalex   +1 more source

Impact of opioid dose escalation on the development of substance use disorders, accidents, self‐inflicted injuries, opioid overdoses and alcohol and non‐opioid drug‐related overdoses: a retrospective cohort study

, 2020
Corey J. Hayes, Erin E. Krebs, Teresa J. Hudson, Joshua D. Brown, Chenghui Li, Bradley C. Martin   +5 more
openalex   +2 more sources

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

Addiction, EarlyView.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring, Tom Tidhar, Anna Olsen, Christopher Bailie, Kelvin Burke, Rowan Martin‐Hughes, Helen Keane, Paul Dietze, Nick Scott   +8 more
wiley   +1 more source

Association of Galanin and Its Receptor Gene Polymorphism with Opioid Dependence: Preliminary Findings from India. [PDF]

Indian J Psychol Med
Naz I, Singh S, Ramawat RB, Kumar R, Quraishi R, Deep R, Ambekar A.   +6 more
europepmc   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Optimizing Control Definitions in Opioid Use Disorder Genetic Research Using Electronic Health Records. [PDF]

Addict Biol
Niarchou M, Tsai EL, Jennings MV, Faucon A, Lee H, Singh K, Tubbs JD, Roussos P, Ge T, Crist RC, Vickers-Smith R, Edenberg H, Moore A, Webb BT, Johnson EO, PsycheMERGE Substance Use Disorder Workgroup, Kember RL, Smoller JW, Davis LK, Coombes BJ, Voloudakis G, Burstein D, Mallard TT, Troiani V, Sanchez-Roige S.   +24 more
europepmc   +1 more source